Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study

Area of Science:

• Cardiovascular disease research
• Medical diagnostics
• Epidemiology

Background:

• Assessing the effectiveness of novel risk markers for coronary heart disease (CHD) prediction is crucial.
• The Framingham Risk Score (FRS) is a standard tool, but its predictive accuracy may be enhanced.
• The Rotterdam Study investigated newer markers against traditional FRS factors.

Purpose of the Study:

• To evaluate if newer CHD risk markers improve the accuracy of the Framingham Risk Score (FRS).
• To compare the predictive capabilities of various novel risk markers against established FRS factors.

Main Methods:

• A prospective, population-based study involving 5933 community-dwelling participants (mean age 69.1 years).
• Collected data on traditional FRS risk factors and newer markers including N-terminal fragment of prohormone B-type natriuretic peptide, von Willebrand factor antigen, fibrinogen, chronic kidney disease, leukocyte count, C-reactive protein, homocysteine, uric acid, coronary artery calcium (CAC) scores, carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity.
• Assessed improvements in CHD risk prediction using c-statistic and net reclassification index.

Main Results:

• Adding coronary artery calcium (CAC) scores to the FRS significantly improved risk prediction accuracy (c-statistic increase: 0.05; net reclassification index: 19.3%).
• N-terminal fragment of prohormone B-type natriuretic peptide also improved predictions, but to a lesser extent (c-statistic increase: 0.02; net reclassification index: 7.6%).
• Other newer markers showed marginal improvements in risk prediction.

Conclusions:

• Coronary artery calcium (CAC) scores offer the most statistically and clinically significant improvement for FRS predictions among the evaluated CHD risk markers.
• Further research is required to determine if CAC score-based risk refinement translates to meaningful clinical outcome changes.
• The generalizability of findings to younger or nonwhite populations is uncertain, and the cost-effectiveness of routine CAC screening warrants careful consideration.